Mallinckrodt appoints new leaders following completion of Questcor acquisition
Mallinckrodt, an Ireland-based global specialty pharmaceutical company, has announced that Gary Phillips, M.D., current senior vice president and chief strategy officer, has been appointed senior vice president and president of the company’s autoimmune and rare disease business, which includes the commercial organization supporting H.P. Acthar Gel.
Additionally, Ray Furey, formerly senior vice president and chief compliance officer at Questcor Pharmaceuticals, has been appointed as senior vice president and the chief compliance officer at Mallinckrodt. The appointments are effective immediately.
Phillips will assume responsibility for the Acthar franchise and all of its sales, support and service activities. He will continue as a member of Mallinckrodt’s executive committee. Furey also will join Mallinckrodt’s executive committee and have a dotted line reporting relationship to the Mallinckrodt board of directors. Both executives will report directly to Mark Trudeau, CEO of Mallinckrodt. A search is underway for the chief strategy officer role.
Phillips has extensive experience with autoimmune disease areas from his past work at Wyeth, Novartis and EMD Serono, and has run large commercial operations as president of Bausch & Lomb’s pharmaceutical and surgical unit as well as president of Reckitt Benckiser Pharmaceuticals.
Furey comes to Mallinckrodt after three years at Questcor leading the company’s strong compliance organization and program. He spent 17 years at Genentech in various capacities, including healthcare compliance, commercial operations, finance, regulatory and manufacturing. Before joining Questcor, Furey was corporate compliance officer at OSI Pharmaceuticals.